Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/f8dc58b3-5d12-40b0-9a39-fe0719478f1f/

ABT

Abbott Laboratories
Chart
103.06 USD
Latest Week 2026-07-24
HealthcareMedical DevicesLARGE
Snapshot 2026-07-26 · 0.6w · Fresh
0.14
OS Score
12.0%
Value
83.0%
Quality
16.0%
Momentum
6/9
F-Score
0.316
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
2 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
2.7%
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
CAQ 0.75
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
12.0%ile
P/E
33.1×
P/S
3.9×
P/B
3.4×
E/P
0.0386
FCF Yield
0.057
EBITDA/EV
0.048
SH Yield
0.027
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
90.00000000
/100 — 1=cheapest
VC2 (Trending Value)
86.00000000
/100
VC3 (Buyback)
86.00000000
/100
P/E of 33.1x is premium-priced — the market is paying up for expected growth. VC2 score of 86.00000000/100 — expensive across all six composite measures.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
83.0%ile
ROE
0.104
ROA
0.049
Net Margin
0.116
Op Margin
0.172
GPA
0.240
D/E
1.11
Current
1.39
F-Score
6/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.081
Earn Growth
-0.612
Stability
1.141
lower=better
Accruals
-0.037
lower=better
5yr Consist
No
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
16.0%ile
6M Return
-3.5%
12M Return
-17.3%
12-1 Mom
-25.0%
Risk-Adj
-1.03
Vol 252d
24.3%
Vol 60d
59.0%
↑ Expanding
Max DD 12M
-37.0%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of -25% signals a downtrend — price is moving against you. Near-term vol (59%) is expanding vs long-term (24%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.14
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
4.4%
Sector Quality %ile
85.8%
P/E z-score
0.11
P/B z-score
-0.14
Sector Avg OS
64.9%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
FBIO Fortress Biotech Inc 99.0% 98.0% 84.0% 87.0%
IRWD Ironwood Pharmaceuticals Inc 99.0% 92.0% 90.0% 98.0%
RIGL Rigel Pharmaceuticals Inc 99.0% 92.0% 93.0% 92.0%
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 97.0%
NUTX Nutex Health Inc 99.0% 93.0% 98.0% 87.0%
TBPH Theravance Biopharma Inc 98.0% 90.0% 99.0% 86.0%
CGEN Compugen 98.0% 90.0% 96.0% 83.0%
INVA Innoviva Inc 97.0% 94.0% 94.0% 67.0%
Factor Interactions
Quality at a Premium
High quality (83th) but expensive (12th value). Upside may be limited without earnings growth.
Volatility Expanding
60-day vol (59%) significantly exceeds 252-day (24%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
C
45.6% avg (7 factors)
Quality
C
50.5% avg (8 factors)
Momentum
F
11.9% avg (4 factors)
Risk
A
76.1% avg (1 factors)
Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends8 snapshots
Factor Persistence8 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.140—8—
Value %ile0.120—8—
Quality %ile0.830—8—
Momentum %ile0.160—8—
F-Score6.000—0—
Confidence0.970—8—
Volatility0.243—0—
Value Lens2021-07-27 → 2026-07-26
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
33.09
Earnings Yield (E/P)
0.0386
Price / Sales
3.85
Price / Book
3.45
Price / Cash Flow
18.77
FCF Yield
5.7%
EBITDA / EV
4.8%
Sales Yield (1/P·S)
0.2246
Shareholder Yield
Div + net buyback / mktcap
2.7%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
10.4%
Return on Assets
4.9%
Net Margin
11.6%
Operating Margin
17.2%
Gross Profit / Assets
Novy-Marx GPA
24.0%
Debt / Equity
1.11
Current Ratio
1.39
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.037
External Financing
Net issuance — lower=better
0.012
MomentumPrice trend strength over different horizons
6M Return
-3.5%
12M Return
-17.3%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-25.0%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-1.03
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
8.1%
Earnings Growth (YoY)
-61.2%
Earnings Stability (CV)
Lower = more stable
1.141
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
6
Dividend Yield
2.4%
Buyback Yield
0.3%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
90
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
86
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
86
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity